Background: This study aimed to investigate the expression and prognostic significance of topoisomeraseII (Topo-II）and c-erbB-2.
Methods: A total of 92 cases of patients with breast cancer who came to our hospital for treatment from November 2013 to January 2016 were included as the experimental group, and 90 healthy subjects who came to our hospital for physical examination during the same period were selected as the control group. ELISA was used to detect the expression levels of Topo-II and c-erbB-2 in serum of each group. The correlation among expression levels, degree of tumor differentiation and pathological types of Topo-II and c-erbB-2 in serum of patients with breast cancer were observed.
Results: The expression levels of Topo-II and c-erbB-2 in the experimental group were higher than those in the control group (P<0.05). The expression levels of Topo-II and c-erbB-2 in serum of patients with different stages increased with the clinical stages. The survival rate of patients with different expression levels of Topo-II and c-erbB-2 was compared, it was found that the survival rate of the low-expression group (80.49%) was significantly higher than that of the high-expression group (50.98%). The ROC curve was used to analyze Topo-II and c-erbB-2, the result showed that the sensitivity, specificity and AUC of Topo-II in the diagnosis of breast cancer was 72.22%, 94.56% and 0.8641, respectively. The sensitivity, specificity and AUC of c-erbB-2 in the diagnosis of breast cancer were 94.45%, 66.30% and 0.8379, respectively.
Conclusions: In conclusion, Topo-II and c-erbB-2 are highly expressed in breast cancer and are closely related to breast cancer. Moreover, the detection of Topo-II and c-erbB-2 in serum can help diagnose gestational diabetes mellitus quickly and effectively.